PDCD1 and nonpapillary renal cell carcinoma: This study confirmed the correlation between M6A modifications and immune status of ccRCC and further validated the prognostic value of the M6A score in programmed cell death protein 1 (PD-1) blockade therapy in patients with advanced ccRCC.